|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 4.160 USD | +1.96% |
|
+0.24% | +45.96% |
| 09-20 | Oramed Pharmaceuticals Inc.(NasdaqCM:ORMP) added to S&P Global BMI Index | CI |
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 170M | - | - | - | - | - |
| 65.28B | |||||
| 54.57B | |||||
| 53.59B | |||||
| 45.03B | |||||
| 42.17B |
Select your edition
All financial news and data tailored to specific country editions
